Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 20 Industry Guidelines Consensus Teaching Materials

The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankylosing Spondylitis with Traditional Chinese and Western Medicine." It is recommended for treating depressive symptoms associated with ankylosing spondylitis (AS) and has been incorporated into 20 industry guidelines/consensus documents.

The "Guidelines for the Diagnosis and Treatment of Ankylosing Spondylitis with Traditional Chinese and Western Medicine," organized by the Standardization Technical Committee of the Chinese Association of Integrated Traditional Chinese and Western Medicine, was officially released in 2023. Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease that primarily affects young men. The guidelines emphasize the higher incidence of depression in AS patients, recommending timely screening using scales or seeking assistance from psychologists. When necessary, pharmacological treatment should be provided, with Jiuwei Zhenxin Granules being considered safe for use either alone or in combination with antidepressants for AS patients with depression.

Jiuwei Zhenxin Granules, independently developed by the company, is the first pure Chinese medicine formulation approved by the National Medical Products Administration for the treatment of generalized anxiety disorder. It is also a key product that the company is actively promoting as a "future star." Since its launch, Jiuwei Zhenxin Granules has received recognition and positive reviews from numerous experts in the field of mental health. The product not only delivers precise efficacy for anxiety disorder patients but also boasts a lower incidence of adverse reactions. Importantly, it carries no risk of addiction or withdrawal.

Jiuwei Zhenxin Granules have been applied in neurology, psychiatry, sleep medicine, gastroenterology, and other departments across thousands of medical terminals nationwide. The company is gradually intensifying its efforts in developing and collaborating on the product's internet-based diagnosis and treatment platform. It has officially entered into a deep collaboration with JD Health's "Yao Jing Cai," listed on JD Pharmacy, and became its "annual strategic partner." The company has also established new collaborations with 1yaowang, Alibaba Health's JD Pharmacy, and Meituan's self-operated JD Pharmacy. Additionally, collaborations with JD Health's Internet Hospital for Real World Data (RWD) research and strategic cooperation with Haoxin Qing Internet Hospital have been initiated, further expanding the sales channels for Jiuwei Zhenxin Granules. Simultaneously, the product has initiated the registration process in Hong Kong and Thailand, laying the groundwork for expanding into overseas markets.

To further enhance the influence of the "Leading Chinese Herbal Anti-Anxiety Brand," Beilu is actively building the "Jiuwei" brand series. Two health products developed around Jiuwei Zhenxin Granules are expected to be approved and launched next year. These products are anticipated to synergize with Jiuwei Zhenxin Granules, constructing a diverse product matrix.